Efficacy and Safety of Bortezomib as First-line Treatment of Acquired TTP
Status:
Not yet recruiting
Trial end date:
2025-11-30
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of bortezomib in the first-line treatment of patients
with acquired TTP，we design this prospective, multi-center, single-arm interventional
study.All enrolled TTP patients were given bortezomib 1.3 mg/m2 intravenous injection d1, 4,
8, on the basis of standard single membrane plasma exchange (2L/d) and hormone therapy
(1mg/kg prednisone or equivalent methylprednisolone). 11 (4 doses in total). Bortezomib
should be administered immediately after each plasma exchange, and the interval between the
next plasma exchange is> 24h. Plasma exchange continued until the patient's platelet count
was >100×109/L for 2 consecutive days, and then changed to once every other day for a total
of two times and then stopped.